Loading…

Neuca S.a.NEU.WACompetitor analysis, valuation and peers

Poland · PLN·Health Care›Medical Distributors
Momentum weak 32
Mkt cap
$795M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$221,053
20-day average traded
Fwd P/E
15.3×
forward earnings
ROIC−WACC
+2.2 pp
WACC 9.3%
Hurdle
-3 pp
Req g minus delivered
Next earnings
1 days
19 Nov 2026
Close · PLNPLN 693.00
1D-1.7%
1W+0.4%
1M-0.4%
3M-8.8%
6M-8.7%
YTD-14.9%
1Y-12.3%
ATR %2.0%
52w lowhigh19.1% off high

What Neuca does

Employees: 4,738

Neuca at a glance

Size Neuca (NEU.WA) is a Poland Health Care company (Medical Distributors) with a market value of $795M, the 45th largest of 82 Poland companies the cockpit tracks. Shares closed at PLN 693.00 on 18 Nov 2026.

Performance Over six months the shares fell 8.7%, against -1.7% for the median peer and +14.0% for the Poland market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 8.4% over the last twelve months (peer median +3.9%); the operating margin is 2.1% (peer median 2.1%).

Valuation It trades at 15.3× forward earnings against a peer median of 15.4× (5th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.2 points above its cost of capital (9.3% WACC).

Next results Next results expected around 19 Nov 2026 (exchange calendar; dates can move).

Relative performance

909510010521 May 202621 Aug 202618 Nov 2026Peer median 99NEU.WA 91
Six months, rebased to 100: Neuca against the median of its 20 peers (local-currency closes).

Neuca financials

Reported figures in PLN; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenuePLN 14.1BPLN 13.6BPLN 12.6BPLN 11.8BPLN 11.2B
Revenue growth—+8%+7%+5%—
Gross profitPLN 1.64BPLN 1.56BPLN 1.44BPLN 1.31BPLN 1.13B
EBITDAPLN 431MPLN 360MPLN 363MPLN 366MPLN 330M
Net incomePLN 197MPLN 156MPLN 154MPLN 146MPLN 137M
Free cash flowPLN 219MPLN 372M-PLN 88.1MPLN 123MPLN 220M
Capital expenditurePLN 130MPLN 125MPLN 92.9MPLN 94.2MPLN 81.4M
Total debtPLN 797MPLN 853MPLN 742MPLN 663MPLN 562M

Quarterly statements and history in the cockpit →

Neuca competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%688366ENTEROARJO-B603368600713301584DOCM74766005876006283013703360605136603716RDC661700007841043151NEU.WA6-month return →1-month return →
Up and to the right = strong over both horizons. Neuca is the large dot.

Fundamentals: revenue growth against valuation

0%+20%20×40×688366ENTEROARJO-B60336874766005873360NEU.WARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Neuca is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%688366ENTEROARJO-B603368301584747660058730137033606051360000783151NEU.WAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Neuca is the large dot.

Neuca competitors and peer comparison

How Neuca compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neuca against its 20 peers (data as of 18 Nov 2026)
MeasureNEU.WAPeer medianRank in peer set
1-month return-0.4%-4.1%8th highest of 21
6-month return-8.7%-1.7%9th lowest of 21
Distance from 52-week high-19.1%-19.8%11th highest of 21
Revenue growth (TTM)+8.4%+3.9%7th highest of 21
Operating margin2.1%2.1%11th highest of 21
Forward P/E15.3×15.4×5th cheapest of 9
Growth the price implies (Req g, 7 yrs)5.3%-1.0%6th most demanding of 16
Growth delivered (Del g)+8.1%+5.7%4th highest of 16
Hurdle (Req g minus delivered)-2.8 pp-5.3 pp7th most demanding of 16
ROIC minus cost of capital+2.2 pp-0.5 pp5th highest of 21
Net debt / EBITDA1.5×0.3×5th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%16.2×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%
Vital KSK 3151.TJapan$399M-1%+3%0%n/a4.7%+2.6%

Questions

Which companies are Neuca's closest peers?
The cockpit's peer set: Shanghai Haohai Biological Technology (688366.SS), Entero Healthcare Solutions (ENTERO.NS), Arjo (ARJO-B.ST), Guangxi LiuYao (603368.SS), Nanjing Pharmaceutical (600713.SS), Shanghai C and D INNOSTIC Medical Technology (301584.SZ), DocMorris (DOCM.SW), AS ONE (7476.T).
Is Neuca expensive compared with its peers?
On forward p/e it trades at 15.3× against a peer median of 15.4×, 5th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Neuca stock performed?
Over six months to 18 Nov 2026 the shares returned -8.7% against -1.7% for the median peer; over one year -12.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.